Clinical Trials Logo

Dravet Syndrome clinical trials

View clinical trials related to Dravet Syndrome.

Filter by:

NCT ID: NCT02229032 Completed - Dravet Syndrome Clinical Trials

Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population

Start date: August 2014
Phase: N/A
Study type: Observational

There is tremendous curiosity about medical marijuana and the treatment of epilepsy. In a specific genetic epilepsy known as Dravet Syndrome, a mutation occurs affecting the SCN1A gene. A specific strain of marijuana known as Charlotte's Web, available in Colorado, may have activity in this catastrophic epilepsy syndrome. Anecdotal reports suggest both success and lack of response with this therapy. Genetic analysis of the differences between Dravet responders and non-responders may prove useful for identifying patients likely to be helped by this therapy, as well as shed light on the putative mechanisms by which marijuana may exert any antiepileptic effect.

NCT ID: NCT02224703 Completed - Epilepsy Clinical Trials

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Start date: April 13, 2015
Phase: Phase 3
Study type: Interventional

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

NCT ID: NCT02224573 Completed - Epilepsy Clinical Trials

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

GWPCARE5
Start date: June 11, 2015
Phase: Phase 3
Study type: Interventional

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.

NCT ID: NCT02091375 Completed - Epilepsy Clinical Trials

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Start date: March 30, 2015
Phase: Phase 3
Study type: Interventional

To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

NCT ID: NCT02091206 Completed - Epilepsy Clinical Trials

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

Start date: October 22, 2014
Phase: Phase 2
Study type: Interventional

To evaluate the safety and pharmacokinetics (PK) of multiple doses of GWP42003-P compared with placebo in children with Dravet syndrome.

NCT ID: NCT01607073 Completed - Dravet Syndrome Clinical Trials

Verapamil as Therapy for Children and Young Adults With Dravet Syndrome

Start date: April 2012
Phase: Phase 2
Study type: Interventional

This study will assess how well the drug verapamil can improve control of seizures and dysautonomia symptoms in children and young adults diagnosed with Dravet syndrome. The safety of verapamil when given with all concomitant medications will also be assessed.